Research programme: disulfide rich peptides - Protagonist Therapeutics

Drug Profile

Research programme: disulfide rich peptides - Protagonist Therapeutics

Alternative Names: Hepcidin agonists - Protagonist Therapeutics; Interleukin-23 receptor antagonist - Protagonist Therapeutics; Nav1.7 voltage gated sodium channel modulators - Protagonist Thearapeutics; PTG 200; PTG-300

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Protagonist Therapeutics
  • Class Disulfides; Peptides
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Hepcidin stimulants; Interleukin-23 receptor antagonists; Nav1.7-voltage-gated-sodium-channel-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Beta-thalassaemia; Haemochromatosis; Neuropathic pain

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Neuropathic pain
  • Research Iron overload

Most Recent Events

  • 14 Nov 2016 Protagonist Therapeutics plans a phase I trial for Crohn's disease
  • 14 Nov 2016 Protagonist Therapeutics plans a phase I trial for Iron overload
  • 28 Jul 2016 Protagonist Therapeutics receives SBIR grant from the National Heart, Lung and Blood Institute for the development of hepcidin mimetics for Iron overload disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top